Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
Clinical trial NCT06849947 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06849947
- Sponsor
- Yeon Hee Park
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-01
- Primary completion
- 2031-06-30
- Enrollment
- 272
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.